Relapse after allogeneic bone marrow transplantation for acute leukaemia

A survey by the E.B.M.T. of 117 cases

F. Frassoni, A. J. Barrett, A. Granena, P. Ernst, G. Garthon, H. J. Kolb, H. G. Prentice, J. P. Vernant, F. E. Zwaan, A. Gratwohl

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

A multi-centre retrospective analysis of 117 patients relapsing after bone marrow transplantation (BMT) for acute leukaemia was carried out by the Leukaemia Working Party of the European Group for Bone Marrow Transplantation (E.B.M.T). Forty-one patients had acute myeloid leukemia (AML) and 76 had acute lymphoblastic leukaemia (ALL). Relapse occurred between 3 and 30 months after BMT and where investigated the leukaemia was found to have relapsed in recipient cells. In 10 cases the relapse was associated with new cytogenetic abnormalities. Of these 21 out of 50 with ALL and 11 out of 24 with AML achieved a complete remission and had a median survival of 12 months compared with a median survival of 4 months for untreated patients or patients not achieving complete remission (P <0.001). Factors predictive for successful induction were a long interval between bone marrow transplant and relapse in ALL patients; and isolated extramedullary relapse. Presenting blast count, karyotype and remission status and number at the time of BMT were not predictive. Donor bone marrow was shown to be responsible for haemopoietic recovery occurring in the 21 out of 31 patients tested who achieved remission using donor karyotype or red blood cell antigens as markers. Nine patients received a second bone marrow transplant but only one became a long-term survivor. The results show that chemotherapy can usually prolong survival in selected patients with acute leukaemia relapsing after BMT but further BMT has a poor outlook.

Original languageEnglish
Pages (from-to)317-320
Number of pages4
JournalBritish Journal of Haematology
Volume70
Issue number3
Publication statusPublished - 1988

Fingerprint

Homologous Transplantation
Bone Marrow Transplantation
Leukemia
Recurrence
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow
Karyotype
Acute Myeloid Leukemia
Survival
Tissue Donors
Transplants
Surveys and Questionnaires
Differentiation Antigens
Chromosome Aberrations
Survivors
Erythrocytes
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Frassoni, F., Barrett, A. J., Granena, A., Ernst, P., Garthon, G., Kolb, H. J., ... Gratwohl, A. (1988). Relapse after allogeneic bone marrow transplantation for acute leukaemia: A survey by the E.B.M.T. of 117 cases. British Journal of Haematology, 70(3), 317-320.

Relapse after allogeneic bone marrow transplantation for acute leukaemia : A survey by the E.B.M.T. of 117 cases. / Frassoni, F.; Barrett, A. J.; Granena, A.; Ernst, P.; Garthon, G.; Kolb, H. J.; Prentice, H. G.; Vernant, J. P.; Zwaan, F. E.; Gratwohl, A.

In: British Journal of Haematology, Vol. 70, No. 3, 1988, p. 317-320.

Research output: Contribution to journalArticle

Frassoni, F, Barrett, AJ, Granena, A, Ernst, P, Garthon, G, Kolb, HJ, Prentice, HG, Vernant, JP, Zwaan, FE & Gratwohl, A 1988, 'Relapse after allogeneic bone marrow transplantation for acute leukaemia: A survey by the E.B.M.T. of 117 cases', British Journal of Haematology, vol. 70, no. 3, pp. 317-320.
Frassoni, F. ; Barrett, A. J. ; Granena, A. ; Ernst, P. ; Garthon, G. ; Kolb, H. J. ; Prentice, H. G. ; Vernant, J. P. ; Zwaan, F. E. ; Gratwohl, A. / Relapse after allogeneic bone marrow transplantation for acute leukaemia : A survey by the E.B.M.T. of 117 cases. In: British Journal of Haematology. 1988 ; Vol. 70, No. 3. pp. 317-320.
@article{d8c321574b814d6aa9c9ea1b4d27d4d7,
title = "Relapse after allogeneic bone marrow transplantation for acute leukaemia: A survey by the E.B.M.T. of 117 cases",
abstract = "A multi-centre retrospective analysis of 117 patients relapsing after bone marrow transplantation (BMT) for acute leukaemia was carried out by the Leukaemia Working Party of the European Group for Bone Marrow Transplantation (E.B.M.T). Forty-one patients had acute myeloid leukemia (AML) and 76 had acute lymphoblastic leukaemia (ALL). Relapse occurred between 3 and 30 months after BMT and where investigated the leukaemia was found to have relapsed in recipient cells. In 10 cases the relapse was associated with new cytogenetic abnormalities. Of these 21 out of 50 with ALL and 11 out of 24 with AML achieved a complete remission and had a median survival of 12 months compared with a median survival of 4 months for untreated patients or patients not achieving complete remission (P <0.001). Factors predictive for successful induction were a long interval between bone marrow transplant and relapse in ALL patients; and isolated extramedullary relapse. Presenting blast count, karyotype and remission status and number at the time of BMT were not predictive. Donor bone marrow was shown to be responsible for haemopoietic recovery occurring in the 21 out of 31 patients tested who achieved remission using donor karyotype or red blood cell antigens as markers. Nine patients received a second bone marrow transplant but only one became a long-term survivor. The results show that chemotherapy can usually prolong survival in selected patients with acute leukaemia relapsing after BMT but further BMT has a poor outlook.",
author = "F. Frassoni and Barrett, {A. J.} and A. Granena and P. Ernst and G. Garthon and Kolb, {H. J.} and Prentice, {H. G.} and Vernant, {J. P.} and Zwaan, {F. E.} and A. Gratwohl",
year = "1988",
language = "English",
volume = "70",
pages = "317--320",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Relapse after allogeneic bone marrow transplantation for acute leukaemia

T2 - A survey by the E.B.M.T. of 117 cases

AU - Frassoni, F.

AU - Barrett, A. J.

AU - Granena, A.

AU - Ernst, P.

AU - Garthon, G.

AU - Kolb, H. J.

AU - Prentice, H. G.

AU - Vernant, J. P.

AU - Zwaan, F. E.

AU - Gratwohl, A.

PY - 1988

Y1 - 1988

N2 - A multi-centre retrospective analysis of 117 patients relapsing after bone marrow transplantation (BMT) for acute leukaemia was carried out by the Leukaemia Working Party of the European Group for Bone Marrow Transplantation (E.B.M.T). Forty-one patients had acute myeloid leukemia (AML) and 76 had acute lymphoblastic leukaemia (ALL). Relapse occurred between 3 and 30 months after BMT and where investigated the leukaemia was found to have relapsed in recipient cells. In 10 cases the relapse was associated with new cytogenetic abnormalities. Of these 21 out of 50 with ALL and 11 out of 24 with AML achieved a complete remission and had a median survival of 12 months compared with a median survival of 4 months for untreated patients or patients not achieving complete remission (P <0.001). Factors predictive for successful induction were a long interval between bone marrow transplant and relapse in ALL patients; and isolated extramedullary relapse. Presenting blast count, karyotype and remission status and number at the time of BMT were not predictive. Donor bone marrow was shown to be responsible for haemopoietic recovery occurring in the 21 out of 31 patients tested who achieved remission using donor karyotype or red blood cell antigens as markers. Nine patients received a second bone marrow transplant but only one became a long-term survivor. The results show that chemotherapy can usually prolong survival in selected patients with acute leukaemia relapsing after BMT but further BMT has a poor outlook.

AB - A multi-centre retrospective analysis of 117 patients relapsing after bone marrow transplantation (BMT) for acute leukaemia was carried out by the Leukaemia Working Party of the European Group for Bone Marrow Transplantation (E.B.M.T). Forty-one patients had acute myeloid leukemia (AML) and 76 had acute lymphoblastic leukaemia (ALL). Relapse occurred between 3 and 30 months after BMT and where investigated the leukaemia was found to have relapsed in recipient cells. In 10 cases the relapse was associated with new cytogenetic abnormalities. Of these 21 out of 50 with ALL and 11 out of 24 with AML achieved a complete remission and had a median survival of 12 months compared with a median survival of 4 months for untreated patients or patients not achieving complete remission (P <0.001). Factors predictive for successful induction were a long interval between bone marrow transplant and relapse in ALL patients; and isolated extramedullary relapse. Presenting blast count, karyotype and remission status and number at the time of BMT were not predictive. Donor bone marrow was shown to be responsible for haemopoietic recovery occurring in the 21 out of 31 patients tested who achieved remission using donor karyotype or red blood cell antigens as markers. Nine patients received a second bone marrow transplant but only one became a long-term survivor. The results show that chemotherapy can usually prolong survival in selected patients with acute leukaemia relapsing after BMT but further BMT has a poor outlook.

UR - http://www.scopus.com/inward/record.url?scp=0023698234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023698234&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 317

EP - 320

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -